학술논문
Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial
Document Type
Article
Author
Source
Subject
*ANTILIPEMIC agents
*DRUG efficacy
*HEAT shock proteins
*STATINS (Cardiovascular agents)
*IMMUNOGLOBULINS
*HYPERLIPIDEMIA
*RANDOMIZED controlled trials
*BLIND experiment
*PLACEBOS
*CROSSOVER trials
*PATIENTS
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0009-9120
Abstract
Abstract: Objective: This study aimed to evaluate the effects of statin therapy on serum levels of antibodies to several specific heat shock proteins (HSPs) in dyslipidemic patients. Design and methods: Participants (n =102) were treated with simvastatin (40mg/day), or placebo in a randomized, double-blind, placebo-controlled, cross-over trial. Anti-HSP60, 65, 70, and hs-CRP levels were measured before and after each treatment period. Seventy-seven subjects completed the study. Results: Treatment with simvastatin was associated with significant reductions in serum anti-HSP60, 65, and 70 titers in the dyslipidemic patients (10%, 14%, and 15% decrease, respectively) (p <0.001). There have been previous reports of reductions in serum CRP with statin treatment, and although median CRP levels were 9% lower on simvastatin treatment, this did not achieve statistical significance. Conclusion: While it is unclear whether HSP antibodies are directly involved in atherogenesis, our findings suggest that simvastatin inhibits autoimmune responses that may contribute to the development of cardiovascular disease. [Copyright &y& Elsevier]